Maxime Dely on The vital Role of Plasma in Immune-Deficient Patients
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”Immunoglobulins: when plasma becomes a vital treatment for immune-deficient patients
Intravenous and subcutaneous immunoglobulins (IVIg, SCIg), produced exclusively from plasma donations, are life-saving medicines.
They replace or support the immune system in a wide range of conditions.
Main indications
- Primary immunodeficiencies (rare and severe congenital disorders)
- Secondary immunodeficiencies (after transplantation, chemotherapy, uncontrolled HIV, etc.)
- Autoimmune and neurological diseases (Guillain-Barré syndrome, myasthenia gravis, Kawasaki disease, immune thrombocytopenia, and more)
Worldwide
Today, millions of patients rely on immunoglobulin therapy every year.
Currently, the global demand is growing steadily (+5–7% annually), driven by broader indications and aging populations.
Unfortunately, there is no synthetic or recombinant alternative today — plasma is the only source.
Immunoglobulins are not only life-saving but also critical for maintaining quality of life in chronic patients.
Behind every infusion of immunoglobulins, there are thousands of plasma donations, transformed into precious medicines.
How can we raise more awareness about the growing importance of plasma-derived immunoglobulins, as global demand keeps rising?”
Stay updated on all scientific advances in the field of transfusion medicine with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening